TEPROTUMUMAB
Drug
Horizon Pharma plc
Total Payments
$174,877
Transactions
9
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $174,877 | 9 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $174,877 | 9 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A MULTICENTER, DOUBLE-MASKED, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF AN INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR IGF-1RANTAGONIST ANTIBODY FULLY HUMAN, IN PATIENTS WITH ACTIVE THYROID EYE DISEASE | Horizon Pharma plc | $118,957 | 0 |
| TED01RV | Horizon Pharma plc | $15,175 | 0 |
| TEPRO 301 | Horizon Pharma plc | $7,006 | 0 |
Top Doctors Receiving Payments for TEPROTUMUMAB
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Milwaukee, WI | $174,877 | 9 |
Ad
Manufacturing Companies
- Horizon Pharma plc $174,877
Product Information
- Type Drug
- Total Payments $174,877
- Total Doctors 0
- Transactions 9
About TEPROTUMUMAB
TEPROTUMUMAB is a drug associated with $174,877 in payments to 0 healthcare providers, recorded across 9 transactions in the CMS Open Payments database. The primary manufacturer is Horizon Pharma plc.
Payment data is available from 2017 to 2017. In 2017, $174,877 was paid across 9 transactions to 0 doctors.
The most common payment nature for TEPROTUMUMAB is "Unspecified" ($174,877, 100.0% of total).
TEPROTUMUMAB is associated with 3 research studies, including "A MULTICENTER, DOUBLE-MASKED, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF AN INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR IGF-1RANTAGONIST ANTIBODY FULLY HUMAN, IN PATIENTS WITH ACTIVE THYROID EYE DISEASE" ($118,957).